Amarin (AMRN) Reports Q3 2025 Earnings Results

Amarin (AMRN) reported strong Q3 2025 earnings with 6% constant currency revenue growth, driven by its pharmaceuticals division and premium intraocular lenses. The company highlighted its robust pipeline and strategic focus on innovation. The CEO emphasized the role of employees and the progress made since 2023.

By Motley Fool Transcribing, The Motley Fool Tue, April 21, 2026 at 7:06 PM GMT+3 44 min read · Yahoo Finance · April 21, 2026, 16:06 UTC

Amarin (AMRN) Reports Q3 2025 Earnings Results

Tickers: $AMRN

Topics: Earnings Call Management Commentary Pipeline Development Product Launches Revenue Growth

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Board Investigation The Verge · November 12, 2026, 15:48 UTC
GFL Environmental Shares Decline Following Preferred Share Conversion and Block Trade Seeking Alpha · November 12, 2026, 15:48 UTC
Medical Facilities Corp. Announces CAD 0.09 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 15:45 UTC
Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC
National Vision Reports Q3 2026 Revenue Growth Driven by Higher Average Ticket Motley Fool · November 12, 2026, 15:40 UTC
Okeanis Eco Tankers Reports Record Q3 2026 Results Driven by High Freight Rates Motley Fool · November 12, 2026, 15:41 UTC
Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC